Core Viewpoint - The company reported 1H25 results that met expectations, with revenue of 1.412 billion yuan, a year-on-year increase of 37.75%, and a net loss attributable to shareholders of 588 million yuan [1] Group 1: Financial Performance - The company's core product revenue was in line with expectations, with product sales reaching 1.402 billion yuan, a year-on-year increase of 49.2% [1] - The gross margin for products was 79.25%, while the sales and marketing expense ratio decreased by 7.1 percentage points year-on-year to 47.80% [1] Group 2: Product Development and Clinical Trials - The company has established a commercialization team of over 1,000 sales personnel to maximize the domestic commercialization potential of its two core products, AK104 and AK112, which have been included in the national medical insurance directory [1] - The final analysis of the HARMONi-A trial showed statistically significant overall survival (OS) benefits for AK112 in treating 2L EGFRm NSCLC, with an OS hazard ratio of 0.80 [2] - AK112 has 13 ongoing registration/Phase III clinical trials globally, covering indications beyond lung cancer, with 8 trials specifically in the lung cancer field [2] Group 3: Profit Forecast and Valuation - The company maintains its profit forecasts for 2025 and 2026, with an upgraded target price of 225.00 HKD, reflecting an 87.5% increase and a 33.1% upside potential [3]

[Table_yemei1] 观点聚焦 Investment Focus 研究报告 Research Report 29 Aug 2025 康方生物 Akeso (9926 HK) 25H1：HARMONi-A 获统计学显著获益结果，建议关注 2025 WCLC 数据催化 25H1: The HARMONi-A study achieved statistically significant benefits; we recommend paying attention to the data catalyst at the 2025 WCLC 公司 25H1 实现营收 14.1 亿元（+37.8%），其中商业化收入 14.0 亿 元（+49.2%），商业化授权收入 0.1 亿元。毛利 11.2 亿元 （+18.8%），毛利率 79.4%（-12.6pcts），商业化毛利 11.1 亿元 （+29.5%）。研发开支 7.3 亿元（+23.0%），研发费用率 51.8% （-6.2pcts），销售费用 6.7 亿元（+29.8%），销售费用率 47.5% （-2.9pcts），行政开支 1.3 亿元（+34.4 ...

Group 1 - On August 28, 2025, the top three companies by trading volume in the Hong Kong Stock Connect (southbound) were SMIC (00981) with a trading volume of 11.618 billion, Meituan-W (03690) with 9.659 billion, and the Tracker Fund of Hong Kong (02800) with 7.940 billion [1][2] - In the Shenzhen-Hong Kong Stock Connect (southbound), the top three companies were Meituan-W (03690) with a trading volume of 6.145 billion, SMIC (00981) with 5.565 billion, and Alibaba-W (09988) with 4.726 billion [1][2] Group 2 - In the Hong Kong Stock Connect (southbound), the net buying amounts for the top three companies were SMIC (00981) with +0.575 billion, Meituan-W (03690) with +0.630 billion, and Alibaba-W (09988) with +0.706 billion [2] - The Tracker Fund of Hong Kong (02800) had a significant net outflow of -7.885 billion, indicating a strong selling pressure [2] - In the Shenzhen-Hong Kong Stock Connect (southbound), Meituan-W (03690) experienced a net outflow of -0.297 billion, while SMIC (00981) had a net inflow of +0.318 billion [2]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed down 1.26% on August 28, with a trading volume of 2.227 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% per year and a custody fee of 0.10% per year [1] - As of August 27, 2024, the fund's latest share count was 6.506 billion shares, with a total size of 6.134 billion yuan, reflecting a year-to-date increase of 1545.50% in shares and 1523.46% in size compared to December 31, 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 88.56% during the tenure [2] - The top holdings of the fund include Innovent Biologics (9.52%), WuXi Biologics (9.47%), BeiGene (8.73%), and others, with their respective market values and share counts detailed [2] - The fund's liquidity is strong, with a cumulative trading amount of 35.359 billion yuan over the last 20 trading days, averaging 1.768 billion yuan per day [1][2]

南向资金今日净卖出204.41亿港元。其中中芯国际、康方生物、华虹半导体净买入额位列前三，分别获 净买入8.92亿港元、5.12亿港元、4.64亿港元。净卖出方面，盈富基金、恒生中国企业、腾讯控股分别 遭净卖出118.86亿港元、47.76亿港元、5.84亿港元。 (本文来自第一财经) ...

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net selling from northbound capital, with a total net sell of 204.41 billion HKD on August 28, 2023, indicating a cautious sentiment among investors [1]. Group 1: Northbound Capital Activity - Northbound capital saw a net sell of 132.97 billion HKD through the Shanghai Stock Connect and 71.44 billion HKD through the Shenzhen Stock Connect [1]. - The most bought stocks included SMIC (00981), Kangfang Biotech (09926), and Huahong Semiconductor (01347), while the most sold stocks were the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises Index (02828), and Tencent (00700) [1]. Group 2: Stock Performance and Predictions - SMIC received a net buy of 8.92 billion HKD, while Huahong Semiconductor had a net buy of 4.63 billion HKD, reflecting a renewed interest in chip stocks [6]. - Kangfang Biotech saw a net buy of 5.11 billion HKD, supported by positive clinical trial results for its drug [6]. - China Life (02628) received a net buy of 3.83 billion HKD, with expectations of steady growth in profits and new business value (NBV) [7]. Group 3: Sector Trends and Market Sentiment - The technology sector showed mixed results, with Meituan (03690) and Alibaba (09988) receiving net buys of 3.33 billion HKD and 3.29 billion HKD, respectively, while Tencent faced a net sell of 5.83 billion HKD [7]. - The AI sector is expected to be a key driver for Hong Kong tech stocks, with improved market sentiment due to easing trade tensions between China and the U.S. [7]. - Horizon Robotics (09660) reported a revenue increase of 67.6% year-on-year, indicating strong growth in the autonomous driving market [8]. Group 4: ETF and Fund Flows - Northbound capital also sold off ETFs, with the Tracker Fund of Hong Kong (02800) and Hang Seng China Enterprises Index (02828) facing net sells of 118.86 billion HKD and 47.76 billion HKD, respectively [9]. - Despite the selling pressure, there is an expectation for continued foreign capital inflow into the Chinese market, although the importance of foreign capital in the Hong Kong market has decreased [9].

Core Viewpoint - CICC reports that Kangfang Biopharma (09926) achieved a 37.75% year-on-year revenue growth in the first half of the year, aligning with the bank's expectations [1] Group 1: Financial Performance - The company's performance meets CICC's expectations, leading to a maintenance of earnings forecasts for the next two years [1] - CICC has raised the target price for the company by 87.5% to HKD 225 [1] Group 2: Product Development - The clinical success rate for AK112 has been upgraded by CICC, and the forecast for the Summit AK112 re-licensing has been included in the valuation [1] - Core drugs, AK104 and AK112, have been included in the national medical insurance catalog, indicating strong clinical advantages and high recognition among medical professionals [1] Group 3: Market Outlook - Given the significant clinical advantages and high acceptance of the products, along with accelerated sales investments by the company, CICC holds an optimistic view on domestic sales for these two products [1]

Core Viewpoint - CICC reports that Kangfang Biopharma (09926) achieved a 37.75% year-on-year revenue growth in the first half of the year, aligning with the bank's expectations [1] Group 1: Financial Performance - The company’s performance meets CICC's expectations, leading to a maintenance of earnings forecasts for the next two years [1] - CICC has raised the target price for the company by 87.5% to HKD 225 [1] Group 2: Product Development - The clinical success rate for AK112 has been upgraded by CICC, and the forecast for the re-licensing of Summit AK112 has been included in the valuation [1] - Core drugs, AK104 and AK112, have been included in the national medical insurance directory, indicating strong clinical advantages and high recognition among medical professionals [1] Group 3: Market Outlook - Given the significant clinical advantages and high acceptance of the products, along with the company's accelerated sales investment, CICC holds an optimistic view on the domestic sales of these two products [1]

Core Viewpoint - The report from交银国际 indicates a significant potential for康方生物's HARMONi study to achieve statistically significant overall survival (OS) results due to a larger sample size [1] Financial Forecasts - The overseas peak sales forecast for康方生物 has been raised to $16.5 billion [1] - The financial projections for the group from 2025 to 2027 have been adjusted [1] - The target price for康方生物 has been increased from HKD 140 to HKD 183, maintaining a "Buy" rating [1] Sales Performance - The company's commercial sales revenue for the first half of the year increased by 49% year-on-year to RMB 1.4 billion [1] - The growth in sales is primarily attributed to the inclusion of the core dual antibody products卡度尼利 and依沃西 in the medical insurance catalog at the beginning of the year [1] - The commercialization of PCSK9 and IL12/IL23 has also contributed to the sales growth [1] - The sales team has over 1,200 members and continues to enhance the oncology and specialty drug divisions [1]

Core Viewpoint - The report from CMB International indicates that with a larger sample size in the HARMONi study, there is a significant likelihood that the final analysis of overall survival (OS) will reach statistical significance [1] Group 1: Financial Projections - The overseas peak sales forecast for the product has been raised to $16.5 billion [1] - The financial forecasts for the group from 2025 to 2027 have been adjusted [1] - The target price has been increased from HKD 140 to HKD 183, maintaining a "Buy" rating [1] Group 2: Sales Performance - The company's commercial sales revenue increased by 49% year-on-year to RMB 1.4 billion [1] - The growth is primarily attributed to the inclusion of core dual-antibody products, Cardunili and Ivosidenib, in the medical insurance catalog at the beginning of the year [1] - The sales team has over 1,200 members and continues to enhance the oncology and specialty drug divisions [1]